Synercid Advisory Committee Nod Driven by Need for VREF Antibiotics
Executive Summary
The over 50% clinical efficacy of Rhone-Poulenc Rorer's Synercid (quinupristin/dalfopristin) in vancomycin-resistant Enterococcus faecium infections demonstrates enough benefit for approval because of the lack of marketed agents for the indication, FDA's Anti-Infective Drugs Advisory Committee concluded Feb. 19.
You may also be interested in...
RPR To Pursue Synercid Pneumonia Indication With Early-2000 Submission
Rhone-Poulenc Rorer will submit results of a second hospital-acquired pneumonia study to FDA in early-2000 to broaden the indication for its injectable streptogramin antibiotic Synercid.
RPR To Pursue Synercid Pneumonia Indication With Early-2000 Submission
Rhone-Poulenc Rorer will submit results of a second hospital-acquired pneumonia study to FDA in early-2000 to broaden the indication for its injectable streptogramin antibiotic Synercid.
Rhone-Poulenc Rorer Targets September Launch For Synercid In U.K.
Rhone-Poulenc Rorer's injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin) is expected to be launched in the U.K. by October, following approval by the Medicines Control Agency on July 29.